X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Varian asset platform VAR-101 is a novel, potential high-potency, specific, aPKCi inhibitor with possible broad use in oncology as well as certain rare malignant diseases.
Lead Product(s): VAR-101
Therapeutic Area: Oncology Product Name: VAR-101
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Varian Biopharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 08, 2024
Details:
The collaboration aims to research on PST2744 (istaroxime), a SERCA2a activator, an important target for the Company’s cardiovascular portfolio, including heart failure.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PST2744
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Chang Gung University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 01, 2024
Details:
Deerfield has agreed to terminate its rights for development and commercial milestone payments associated with AEROSURF®, an acute pulmonary drug/device combination intended to treat premature infants with respiratory distress syndrome.
Lead Product(s): Lucinactant
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Aerosurf
Highest Development Status: Phase IIProduct Type: Peptide
Recipient: Deerfield Management
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination January 25, 2024
Details:
Under the agreement, Lee will be responsible for the development and commercialization of Windtree’s product candidate PST2744 (istaroxime), a first-in-class dual-mechanism therapy, in Greater China, including for acute heart failure and cardiogenic shock.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PST2744
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lee’s Pharmaceutical
Deal Size: $138.1 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 17, 2024
Details:
PST2744 (Istaroxime) is a Na/K ATPase 2 inhibitor & a first-in-class dual mechanism therapy designed to improve both systolic and diastolic cardiac function. It is under phase 2 clinical development for the treatment of cardiogenic shock.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PST2744
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
PST2744 (istaroxime) is a novel first-in-class therapy that is designed to improve systolic contraction and diastolic relaxation of the heart while also increasing blood pressure. It is under phase 2 clinical development for the treatment of Early Cardiogenic Shock.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PST2744
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
TH1902 (sudocetaxel zendusortide)sudocetaxel zendusortide, an investigational, first-in-class peptide-drug conjugate (PDC) that targets the sortilin (SORT1) receptor and expedites the internalization and delivery of a cytotoxic payload directly into cancer cells.
Lead Product(s): Sudocetaxel Zendusortide
Therapeutic Area: Oncology Product Name: TH1902
Highest Development Status: Phase IProduct Type: Peptide
Recipient: Theratechnologies
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2023
Details:
The Company intends to use the net proceeds of the offering to extend enrollment and complete a Phase 2 clinical trial for PST2744 (istaroxime), a potent inhibitor of Na+,K+-ATPase, in cardiogenic shock.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PST2744
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ladenburg Thalmann & Co. Inc.
Deal Size: $12.4 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 24, 2023
Details:
The Company will use the proceeds to extend enrollment and complete a Phase 2 clinical trial for PST2744 (istaroxime), a positive inotropic agent that mediates its action through inhibition of sodium/potassium adenosine triphosphatase (Na+/K+ ATPase), in cardiogenic shock.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PST2744
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ladenburg Thalmann & Co. Inc.
Deal Size: $10.8 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 20, 2023
Details:
PST2744 (istaroxime) is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism of the SERCA2a calcium pump activation on the sarcoplasmic reticulum enhancing calcium reuptake from the cytoplasm.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PST2744
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
